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ABSTRACT
Introduction Few studies have assessed the efficacy of 
smoking cessation interventions in individuals with type 2 
diabetes, but interventions adapted to the specific needs 
of this population are warranted. The aim of this study is 
to assess the efficacy of a smoking cessation intervention 
in a population of smokers with type 2 diabetes and to 
measure the metabolic impact of smoking cessation.
Methods and analysis The study is an open- label, 
randomised control trial. Participants recruited from a 
sanitary region of Switzerland will be randomly allocated to 
either the intervention or the control arm. The intervention 
group will have four individual counselling sessions over 
12 weeks. Trained research nurses will conduct the 
behavioural intervention, using motivational interviews 
and addressing diabetes and gender specificities. The 
control group will have one short counselling session at 
baseline and will be given written information on smoking 
cessation. Both groups will have a follow- up visit at 26 
and 52 weeks. Demographic and medical data will be 
collected at baseline and follow- up, along with blood and 
urine samples. The primary study outcome is continuous 
smoking abstinence validated by expired- air carbon 
monoxide from week 12 to week 52. Secondary study 
outcomes are continuous and 7- day point prevalence 
smoking abstinence at 12 and 26 weeks; change in 
motivation to quit and cigarette consumption; and change 
in glycosylated haemoglobin levels, body weight, waist 
circumference and renal function after smoking cessation. 
In a subsample of 80 participants, change in stool 
microbiota from baseline will be measured at 3, 8 and 26 
weeks after smoking cessation.
Ethics and dissemination Ethical approval has been 
obtained by the competent ethics committee (Commission 
cantonale d’éthique de la recherche sur l’être humain, 
CER- VD 2017–00812). The results of the study will be 
disseminated through publications in peer- reviewed 
journals and conference presentations.
Trial registration numbers  ClinicalTrials. gov 
NCT03426423 and SNCTP000002762; Pre- results.
INTRODUCTION
Smoking is the leading cause of avoidable 
death worldwide and among the top five 
causes of morbidity and decreased disability- 
adjusted life- years.1 More than a quarter of the 
Swiss population currently smokes cigarettes.2 
Similarly, diabetes is a major public health 
problem and its burden is increasing glob-
ally.3 In Switzerland, it is estimated that about 
450 000 people have diabetes, more than 90% 
of them having type 2.3 Smoking increases 
the risk of developing type 2 diabetes, and 
people with type 1 and type 2 diabetes who 
smoke are at increased risk of complications 
and premature death.4–6 Avoiding tobacco 
use could prevent a large proportion of cases 
of diabetes and its complications.7
Strengths and limitations of this study
 ► Smokers with various degrees of motivation to quit 
(including smokers not motivated to quit) are includ-
ed with few exclusion criteria to ensure high external 
validity and thus clinical generalisability.
 ► The 12- month follow- up will assess the long- term 
efficacy of the behavioural smoking cessation 
intervention.
 ► The smoking cessation intervention is tailored to di-
abetes and gender specificities.
 ► The smoking cessation intervention is compared 
with usual care; thus, participants in the control 
group might benefit from other interventions that 
may contaminate the control group.
 ► As a result of group heterogeneity and few exclusion 
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Smoking prevalence and impact on people with diabetes
In those with diabetes, smoking has been repeatedly 
shown to increase the risk of mortality,8–12 as well as 
macrovascular complications such as coronary heart 
disease13–16 and stroke.17 Regarding microvascular compli-
cations, smoking has been shown to increase the risk of 
developing or worsening nephropathy, retinopathy18 and 
peripheral neuropathy.6
Despite the high rate of complications related to ciga-
rette smoking, smoking prevalence remains high among 
people with diabetes.19–21
Smoking cessation in people with diabetes
It is a challenge for clinicians to induce a change in the 
behaviour of people with diabetes and to encourage a 
healthy lifestyle.22 Smokers with diabetes might differ 
from other smokers regarding not only their risks, but 
also their reasons for smoking and motivations to quit. 
Evidence suggests that they are less motivated to quit than 
other smokers, possibly because they fear weight gain.23 24 
Smokers with diabetes are also more likely to have depres-
sion,23 25 a condition that has been shown to hinder efforts 
to stop smoking.26 In addition, they may be inadequately 
informed about the benefits of smoking cessation or avail-
able options to help them quit.27 28 These factors explain 
in part why success rates for smoking cessation are often 
low among people with diabetes.29 Most smokers with 
diabetes are not aware of the important risk of microvas-
cular and macrovascular complications associated with 
smoking30 and often do not perceive smoking cessation 
as a top priority.31 32 Rather, diabetic smokers are most 
concerned about their weight, dietary adherence and 
diabetes management.33 Moreover, health professionals 
might be less prone to give smoking cessation advice to 
people with diabetes.27
Limited evidence is available on the effectiveness and 
efficacy of smoking cessation interventions in people with 
diabetes. Several studies have tested multifactorial inter-
ventions (which included smoking cessation in addition to 
other interventions such as physical activity) with various 
levels of intensity.34–38 Some studies showed an increase in 
smoking abstinence in participants who received multi-
factorial intervention,36 but the effect of smoking was 
difficult to isolate or the studies lacked power to show 
significant results when restricted to smokers.35
A systematic review and meta- analysis, published in 
2014, summarised randomised control trial studies that 
assessed smoking cessation interventions among people 
with diabetes.39 In this review, which included four 
studies, smoking cessation rates at 6 months were vari-
able, ranging from 0% to 18%, and the overall risk ratio 
of smoking cessation, which compared more intensive 
with less intensive smoking cessation interventions, was 
non- significant (risk ratio 1.32, 95% CI 0.23 to 7.43) using 
a random- effects model.
The few studies that have prospectively assessed the 
impact of smoking cessation on diabetes control and 
complications show contradictory findings. In a case 
control study from Japan that included 31 participants 
with type 2 diabetes, smoking cessation was associated 
with an increase in body weight (+1.2 kg), glycosylated 
haemoglobin (HbA1c) levels (+1 unit) and systolic and 
diastolic blood pressure at 12 months compared with 
continuing smoking.40 In contrast, in a 12- month obser-
vational study that included 193 participants with newly 
diagnosed type 2 diabetes, smoking cessation was asso-
ciated with improvement in microalbuminuria, insulin 
resistance, and glycaemic control and with a reduction in 
peripheral vascular disease and polyneuropathy, but it had 
no effect on retinopathy.41 Chaturvedi et al showed that 
former smokers with diabetes had a lower risk of mortality 
than did continuing smokers, risk attenuation increasing 
with length of cessation.42 In a study that included men 
only, smoking cessation was estimated to be the best way 
to prolong life in people with diabetes compared with 
other interventions for reducing cardiovascular risk 
factors.43 Thus, smoking cessation is highly beneficial for 
long- term outcomes among diabetic patients, but little is 
known about short- term outcomes such as weight gain 
and diabetes control following smoking cessation.
Smoking, diabetes and microbiota
Studies recently reported modifications of intestinal 
and oral/nasopharyngeal microbial flora after smoking 
cessation in non- diabetic human subjects.44–46 It has been 
hypothesised that a change in the microbiota among non- 
diabetic smokers (a change to ‘obesogenic’ flora) after 
smoking cessation might partly explain weight gain.45 
Fingerprinting of the microbiota has been studied in 
people with diabetes and compared with that in cardio-
vascular and control groups. The diabetes group showed 
a significantly increased proportion of aerobic bacteria, 
an increased proportion of coliforms, and a reduced 
proportion of bifidobacteria; the balance between bene-
ficial and pathogenic bacteria was disturbed among those 
with diabetes.47 Moreover, the increased proportion of 
coliforms (with highly active lipopolysaccharide) and 
aerobic bacteria might result in an increased rate of intra-
luminal inflammation and dysbiosis, possibly leading in 
some susceptible persons to irritable colon syndrome or 
inflammatory bowel disease. The design of the studies that 
assessed the change in microbiota after smoking cessa-
tion and the limited number of subjects makes it difficult 
to generalise the results. Furthermore, no studies have 
prospectively assessed the impact of smoking cessation on 
the gut microbiota of subjects with type 2 diabetes.
Smoking, diabetes and gender
The prevalence of type 2 diabetes seems to be higher 
among men than among women.48 Risk factors for 
diabetes and complications seem also to differ between 
men and women, as diabetes confers a higher cardiovas-
cular disease risk among women.49–51 Concerning diabetes 
process of care, women have better glycaemic control 
and adherence to recommended self- care than men do.52 
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aspirin or antihypertensive or lipid- lowering drugs, and 
are treated less aggressively, thus gaining poorer control 
over their cardiovascular disease risk factors than men 
can.53–55
Despite an overall decrease in smoking prevalence 
over the past decades in high- income countries,56 the 
gap between men and women smokers has narrowed.57 
Women have different reasons and motivations to smoke 
than men do.58 59 They are more likely to use cigarettes as 
a strategy to manage their weight and to cope with stress 
and emotions.58 60 61 Furthermore, women have different 
concerns associated with quitting, such as weight gain.62 63 
They have a higher perceived risk of quitting and are 
more likely to relapse because of weight gain.64 65 It is, 
thus, important to take into account gender and diabetes 
specificities to better address barriers to quitting and to 
improve success in smoking cessation.
Smoking, diabetes, social stigma and depression
Recent research has shown that patients with type 
2 diabetes experience social stigma, as diabetes is 
portrayed as the ‘blame and shame’ disease associated 
with bad lifestyle habits (nutrition, sedentary behaviour, 
smoking).66–69 Sources of diabetes- related social stigma 
include the media, healthcare professionals, friends, 
family and colleagues. Social epidemiologists have 
provided evidence on the effect of social stigma on 
psychosocial stress, leading to hypertension and other 
poor health outcomes.70 71 They are pleading for further 
studies to include both individual- level and structural- level 
measures of stigma and their effect on health outcomes. 
It is hypothesised that diabetes social support groups and 
motivational interviews can play a role in reducing the 
structural stigma experienced by diabetic persons, and 
thus its psychosocial effect on health.
In addition, the bidirectional association between 
diabetes and depression is well established.72 In fact, 
while depression is often perceived as a consequence of 
diabetes due to the burden of chronic illness, research 
has shown that depression may be a risk factor for the 
development of diabetes, explained by the biochemical 
changes and poor health- related behaviour in persons 
with depression.72 It is here hypothesised that the motiva-
tional interview, which includes a depression component, 
has an effect on diabetes self- care management on the 
one hand, and allows screening and appropriate referral 
in case of depression on the other.
Rationale for the study
In the latest US guidelines for treating tobacco use 
and dependence, the authors conclude that additional 
research is needed on counselling, cessation medications, 
and the impact and effectiveness of tailored interventions 
in individuals with diabetes.73 The purpose of the current 
study is to evaluate the efficacy of a smoking cessation 
intervention tailored to diabetes and gender needs 
among type 2 diabetic smokers. The secondary purpose 
is to measure and compare the metabolic consequences 
of smoking cessation and the influence of gut microbiota 
on metabolism among type 2 diabetics who successfully 
quit smoking and among those who continue to smoke. A 
substudy explores the relationship between social stigma, 
depression and diabetes self- care management.
METHODS AND ANALYSIS
Design
A total of 500 participants will be randomly assigned to 
either the intervention or the control group by using a 
computer- generated allocation method (orange area of 
figure 1). Allocation will be stratified by sex in order to 
obtain the same proportion of men and women in both 
groups.
Intervention
The intervention consists in behavioural smoking cessa-
tion. Combined pharmacotherapy and behavioural 
interventions have been shown to be effective in helping 
smokers to quit in the general population.73 74 For the 
present study, we will use an evidence- based smoking 
cessation intervention and tailor it to the participants 
from the findings of the previous phases of our study.75
The smoking cessation intervention will be standardised 
and follow Swiss and international guidelines.73 76 77 It will 
include both psychosocial support and evidenced- based 
pharmacotherapy treatment, which produce higher 
success rates when combined.74 78 79 Counselling will cover 
topics such as assessing ambivalence and enhancing moti-
vation with motivational interviewing methods80 (using, 
eg, past successes in the field of smoking cessation or 
other lifestyle changes such as diet or physical activity), 
identifying barriers to quit (that are specific to people 
with diabetes, such as weight and diabetes management), 
coping with cravings and intensive relapse prevention 
strategies. Participants will be advised to use over- the- 
counter nicotine replacement therapy (NRT). A 2- week 
starting kit will be provided, consisting of a nicotine trans-
dermal patch, and a short- acting NRT will be provided to 
participants for free.
The behavioural intervention will last 30–45 min and 
will be conducted by research nurses. These study nurses 
will take basic training in motivational interviewing (certi-
fied training of 4 sessions of 4 hours each). They will have 
an interview guide that will be flexible enough to adapt 
Figure 1 Diabetes and Smoking Cessation: a Gender- 
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to the patient’s stage of motivation and preferences, as 
suggested by motivational interviewing techniques.
The intervention will follow the 5A steps, which is a 
well- described and systematic model currently being used 
in our smoking cessation outpatient clinic:
Ask for smoking status: The nurse will ask at each visit if 
the participant has smoked during the last 24 hours, the 
number of cigarettes (or other tobacco product) smoked, 
and the date of the last cigarette.
Assess motivations and need to quit: The nurse will 
assess the overall motivation to quit and the confidence 
to quit in the participants by using Likert scales from 1 
to 10. She/he will also discuss with the participants their 
specific motivations to quit, as well as barriers and needs.
Advise about the possibility of smoking cessation and 
its benefits: The nurse will give information specific to 
diabetes that is adapted to the needs of the participants. 
This advice will be given by using recommended motiva-
tional interview techniques.
Assist the smoker to quit or decrease smoking by 
using a motivational interview±NRT: The nurse will then 
assist the participant to quit or change his/her cigarette 
consumption. No pressure will be put on smoking cessa-
tion, that is, no quit date will be fixed, unless the partic-
ipant is ready and willing to quit, and every step towards 
a decrease in consumption will be encouraged. NRT will 
be systematically proposed to the participants in the inter-
vention group who are willing to quit or decrease their 
consumption, but will be optional.
Arrange follow- up with the participant with 3 contacts of 
30 min at weeks 3, 8 and 12, in which the nurse will again 
address smoking cessation by using the 5As approach, 
motivational interviewing and cognitive–behavioural 
techniques.
Control group
Participants assigned to the control group will receive a 
less intensive and non- tailored intervention for smoking 
cessation. For this arm the structured three steps ‘Ask, 
Advise, Refer’ or ‘AAR’ approach will be used: Ask for 
smoking status. Advise to quit in a clear manner. Refer 
to external help: participants will receive a booklet with 
written information on smoking cessation (non- specific 
to diabetes and gender) and links to support facilities 
(national quitline, smoking cessation clinic, websites, 
self- help). This unique intervention of 5–10 min will be 
performed by the research nurse.
Patient and public Involvement
This study, DISCGO- RCT (Diabetes and Smoking Cessa-
tion: a Gender- Oriented Randomised Controlled Trial) is 
the next phase of the DISCGO- MIX study (CER- VD project 
ID: 302/15, Swissethics ID PB_2016–01459) (purple area 
of figure 1; see also below for details), which is intended 
to define the beliefs, motivations and specific needs of 
diabetic smokers by using a mixed- methods approach.75 
Using qualitative methods, we explored patients with 
diabetes and healthcare provider’s experiences and 
priorities. We adapted the intervention on the basis 
of their comments and preferences (eg, no interest in 
group sessions, desire for a motivational and ‘guilt- free’ 
approach). We did not discuss the design of the study 
with patients and did not include them in conducting the 
study. Nevertheless, we contacted patients’ associations to 
help us recruit participants and diffuse information. We 
plan to send the participants the main results individu-
ally by using a simple factsheet with pictograms. We did 
not assess the burden of the intervention by the patients 
themselves before the start of the study.
Sample size
Power calculations indicate that a sample size of approx-
imately 400 people is needed for the primary endpoint, 
that is, to detect a 10% difference in smoking abstinence 
between the intervention and control groups at 52 weeks 
with a 2- sample proportions test by using Pearson’s χ2 
test (power 80%, significance level 0.05). From previous 
studies in the general population, smoking cessation 
rates are around 5%–20% without interventions.45 If we 
hypothesise that smoking abstinence in the control group 
will be 10% at 12 months, an increase of 10% in the inter-
vention group, that is, a 12- month smoking abstinence 
of 20%, would be considered clinically significant. We 
hypothesise a 20% attrition rate; therefore, the sample 
will be increased to 500 participants.
The analyses on the impact of smoking cessation on 
microbiota are exploratory and no sample size calcula-
tions have been performed. We will use a convenience 
sample of 80 participants (metabolic cohort).
Outcomes
The primary outcome is to assess the efficacy of a 
personalised smoking cessation behavioural interven-
tion compared with usual care on validated continuous 
smoking abstinence among type 2 diabetic smokers for up 
to 52 weeks (see below and figure 2). The study calendar, 
including all visits, measures and questionnaire details, is 
shown in table 1. Outcome measures are summarised in 
table 2.
Smoking abstinence will be defined as a continuous 
abstinence rate from week 12 (end of intervention) to 
week 52 (end of follow- up), as recommended by the 
quality criteria for measuring smoking abstinence.81 
Abstinence at each visit will be defined as a self- report of 
no smoking or use of other nicotine- containing products 
(electronic nicotine delivery system, smokeless tobacco) 
since the previous visit or contact, as confirmed by an 
expired carbon monoxide (CO) level of <10 ppm.81 82
The secondary outcomes for smoking cessation are as 
follows:
 ► Continuous smoking abstinence validated by CO at 12 
and 26 weeks.
 ► 7- day point prevalence abstinence validated by CO at 
12, 26 and 52 weeks.
 ► Change in motivation to quit and number of quit 
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 ► Harm reduction (decrease of ≥50% of cigarette 
consumption) at 12, 26 and 52 weeks.
The secondary metabolic endpoints are as follows:
 ► Change in body weight and waist circumference from 
baseline to 12, 26 and 52 weeks.
 ► Change in HbA1c levels from baseline to 12, 26 and 
52 weeks.
 ► Change in renal function as assessed by the estimated 
glomerular filtration rate (eGFR) (Chronic Kidney 
Disease- Epidemiology Collaboration (CKD- EPI) 
creatinine- based formula) and albumin/creatinine 
ratio from baseline to 12, 26 and 52 weeks.
The exploratory endpoint (metabolic cohort) is as 
follows:
 ► Change in faecal microbiota from baseline to 3, 8 and 
26 weeks. Different alpha and beta- diversity indexes 
will be used to characterise and compare the micro-
biota. Moreover, the rate of aerobic vs anaerobic 
bacteria, as well as the proportion of so- called benefi-
cial gut bacteria such as species of Faecalibacterium and 
Akkermansia, will be compared between the different 
study groups.
The exploratory substudy on social stigma and depres-
sion will investigate the following:
 ► Association between social stigma (using the Everyday 
Discrimination Scale (EDS))83 84 and diabetes self- 
care management (using the Summary of Diabetes 
Self- Care Activities (SDSCA))85 and between the EDS 
and HbA1c levels.
 ► Association between depression (using the Patient 
Health Questionnaire for Depression (PHQ-9))86 and 
diabetes self- care management (using the SDSCA) 
and between the PHQ-9 and HbA1c levels.
 ► Change in PHQ-9 score from baseline to 52 weeks.
Study population
Participants fulfilling all of the following inclusion criteria 
are eligible for the study:
 ► Informed consent as documented by signature.
 ► Having smoked >100 cigarettes during his/her entire 
life and currently smoking cigarettes (no minimal 
threshold).
 ► Having been diagnosed with type 2 diabetes.
 ► Being ≥18 years old.
 ► Speaking and understanding French.
The presence of any one of the following exclusion 
criteria will lead to exclusion of the participant:
 ► Not being able to give informed consent and to follow 
the study procedure (due to dementia, psychological 
disorder, language problem).
 ► Being pregnant or breast feeding.
 ► Being enrolled in another smoking cessation study or 
programme or in a multibehavioural programme that 
includes smoking cessation.
 ► Enrolment of the investigator or other research 
collaborators, their family members, employees and 
other dependent persons.
 ► Planning to move out of Switzerland within the next 
year.
Inclusion and exclusion criteria for the renal secondary 
outcome:
 ► Same inclusion and exclusion criteria as above and,
 ► CKD with Kidney Disease Improving Global Outcomes 
CKD stage G3-5 (eGFR <60 mL/min based on the 
formula CKD- EPI (creatinine)) and/or stage A3 
(urinary albumin/creatinine ratio >30 mg/mmol on 
a urinary spot).
Recruitment and screening
Participants will be recruited from the Lausanne Univer-
sity outpatient clinics; medical or surgical wards (after 
discharge) of the Lausanne University Hospital; private 
practices of general internists and specialists in endo-
crinology from the region of Lausanne; the community 
via advertisements on selected websites, newspapers and 
social networks; pharmacies; and ambulatory centres 
from peripheral hospitals within a radius of 20–30 km 
around the investigation centre.
We will establish a list of all patients who have been 
admitted to the Lausanne University Hospital or outpa-
tient clinic with a diagnosis of type 2 diabetes and a 
documented smoking status. Patients will be invited to 
participate to the study by letter. We will also post the 
information about study recruitment on the outpatient 
clinic website and on screens located in the waiting rooms. 
For participants recruited from pharmacies and private 
practices of generalists and/or specialists, flyers will be 
proactively distributed to potentially eligible patients by 
healthcare providers or local staff.
Analysis plan
Analyses for the primary outcome and secondary 
outcomes on smoking cessation will be done on an 
Figure 2 Randomised controlled study design with nested 
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intention- to- treat basis. Participants lost to follow- up will 
be considered continuing smokers.
Primary analyses
Continuous smoking abstinence between weeks 12 and 
52 will be compared between the intervention and the 
control group by using a Pearson χ2 test with a signifi-
cance level of p<0.05. Analysis on the primary endpoint 
will be done by the research statistician, who will be blind 
to study groups. Similar analyses will be performed for 
other smoking cessation outcomes.
Stratified analyses for sex will be performed, with a χ2 
test for analysing association between intervention and 
smoking cessation outcomes separately for each sex.
A logistic model for all smoking cessation (dichoto-
mous) outcomes will be performed. The last (equivalent 
to the χ2 test in the unadjusted case) will allow us to:
1. Adjust for the type of smoking cessation treatment or 
help used by participant and not included into the 
study programme (participants will be free to use any 
smoking cessation treatment or help).
2. Test the effect of the interaction between intervention 
and sex on smoking abstinence for all outcomes, in or-
der to explore if the intervention acts differently for 
the two sexes on the chances to stop smoking.
A longitudinal (generalised estimating equation) 
model will be used to compare abstinence trajectories 
between control and intervention groups, also adjusting 
for sex.
Secondary analyses
For metabolic outcome analyses on the nested metabolic 
cohort, the data will be used as a cohort and comparisons 
will be made between smokers who have managed to quit 
and continuing smokers.
A change in HbA1c levels from baseline will be 
compared between quitters and continuing smokers at 6 
and 12 months by using t- tests with a significance level of 
p<0.05 after verification of normality. Among quitters, we 
will perform supplementary analyses creating subgroups 
of quitters according to time since quitting (long- term vs 
short- term quitters).
The prevalence of diabetes control, defined as HbA1c 
levels of <7%, will be compared between quitters and 
continuing smokers at 6 and 12 months. Stratified and 
adjusted analyses for sex will be performed to assess 
whether there is a differential metabolic impact of 
smoking cessation between men and women (interaction 
sex/smoking cessation in a logistic model for diabetes 
control).
We will assess the potential role of mediating factors in 
the association between smoking cessation and glycaemic 
control (HbA1c continuous) or diabetes control (HbA1c 
levels of <7%) such as weight gain, waist circumference 
and high- sensitivity C reactive protein. To assess the 
potential role of these mediating factors, we will enter 
them in turn in a logistic or linear models and evaluate 
their potential influence on the estimate (potential medi-
ating effect if we observe a >10% change in the estimate).
Similar analyses will be performed for other labora-
tory variables (lipid profile, microalbuminuria, thyroid- 
stimulating hormone).
Descriptive statistics will be performed to compare 
changes in faecal microbiota from baseline to 4, 8 and 26 
weeks between quitters and continuing smokers. Analyses 
will be adjusted for the intervention group, baseline body 
mass index, change in weight, waist circumference, age, 
sex, change in diabetes therapy and other treatments, 
and use of nicotine. In addition to the classic phylum- 
level analysis, we will also assess the impact of smoking 
cessation on diversity by using various indexes such as 
Shannon and on the presence or absence of various 
species-, genus- and family- level lineages. This analysis will 
first imply an assignment of the reads and then a subse-
quent description of the species, genus and family that 
are present in large amounts at baseline. A description of 
the variations of these specific species- level, genus- level 
and family- level lineages will then be assessed.
Substudy analyses
For the substudy, we will cross- sectionally (at w52) explore 
the association between social stigma (using EDS) and 
diabetes health outcomes (SDSCA and HbA1c levels), as 
well as between depression (PHQ-9) and the same health 
outcomes. To explore the hypothesis that social support 
may decrease social stigma, perceived stress and depres-
sion, and ultimately diabetes outcomes, we will further 
explore the path models between social support (diabetes 
support groups and/or motivational interview) and 
diabetes outcomes by using a structural equation model-
ling (SEM) approach87 (hypothetical model as online 
supplemental material). We will develop a theory- driven 
SEM model (path diagram) using the constructs repre-
sented by latent factors (eg, social stigma, SDSCA) based 
on the literature and hypotheses. We will then, in an 
exploratory step, use study data for model respecification 
and fit testing, ensuring meaning of items and factors is 
maintained and theoretically explained.
Data management
Data will be collected by using electronic case record 
forms (Research Electronic Data Capture (REDCap) 
software) that will be securely stored for 10 years. Stata 
V.16.0 (StataCorp) and R (R Foundation for Statistical 
Computing, Vienna, Austria) will be used for statistical 
analyses.
ETHICS AND DISSEMINATION
Before the study started, the protocol, patient informa-
tion and consent form, as well as other study- specific 
documents, were submitted to the appropriately consti-
tuted CEC (ie, Commission cantonale d’éthique de la 
recherche sur l’être humain du canton de Vaud, CER- 




















pen: first published as 10.1136/bm






11Clair C, et al. BMJ Open 2020;10:e040117. doi:10.1136/bmjopen-2020-040117
Open access
formal approval. Approval was obtained on 28 December 
2017. The study started in March 2018 and is ongoing. 
Any amendment to the protocol will be sent to the CEC 
for approval.
The study will be carried out in accordance with the 
protocol and with the principles in the current version 
of the Declaration of Helsinki,88 the guidelines of Good 
Clinical Practice issued by the International Conference 
on Harmonization,89 90 Swiss law91 and the requirements 
of the Swiss regulatory authority.92 93 The CEC will receive 
annual safety and interim reports and be informed about 
study stop/end in agreement with local requirements.
Risk- based monitoring will be performed by the Clin-
ical Trial Unit, Lausanne (Switzerland).
The results of the study will be communicated and 
disseminated through conference presentations in 
national and international congresses of general internal 
medicine, endocrinology and tobacco research fields 
and through peer- reviewed manuscripts published in 
open- access journals. Depending on the results, we will 
propose implementing a smoking cessation intervention 
programme based on our model in diabetes clinics and 
in ambulatory care of our sanitary region (French part of 
Switzerland).
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